BioNTech to price vaccine with Pfizer below market rates

  • 📰 thenewpaper
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

United States News News

FRANKFURT: BioNTech, first in the race to produce evidence of a working Covid-19 vaccine together with Pfizer, is planning to price the two-shot regimen below 'typical market rates' and would differentiate pricing among countries or regions. But with tropical heat, remote...

But health experts cautioned that the vaccine, should it be approved, was no silver bullet - not least because the genetic material it is made from needs to be stored at temperatures of minus 70 deg C or below.

That is a problem given the World Health Organisation estimates 70 per cent of people must be inoculated to end the pandemic, and Asia alone is home to more than 4.6 billion - or three-fifths of the global population. "On the cold chain requirement of minus 70 deg, that is a hefty requirement. We do not have such a facility," Philippines' Health Secretary Francisco Duque told Reuters.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 7. in US

United States United States Latest News, United States United States Headlines